What risperidone dose is equivalent to 5 mg olanzapine?

Risperidone Equivalent Dose for 5 mg Olanzapine

The risperidone dose equivalent to 5 mg olanzapine is approximately 1.5 mg per day. 1

Evidence-Based Dose Equivalence

The most direct and recent guideline evidence establishes a clear conversion ratio between these two atypical antipsychotics:

• Olanzapine 7.5 mg is equivalent to risperidone 2 mg in clinical practice, based on comparative efficacy and receptor occupancy data 1
• Using this established ratio (7.5 mg olanzapine = 2 mg risperidone), 5 mg olanzapine converts to approximately 1.3–1.5 mg risperidone 1
• An alternative evidence-based calculation using minimum effective doses yields a similar result: olanzapine 5 mg corresponds to risperidone 2 mg based on chlorpromazine equivalents (100 mg chlorpromazine = 5 mg olanzapine = 2 mg risperidone) 2

Supporting Research Evidence

Multiple high-quality studies corroborate this dose relationship:

• First-episode psychosis trials used mean doses of 4 mg/day risperidone versus 15.3 mg/day olanzapine with equivalent efficacy, suggesting a roughly 1:4 ratio 3
• Head-to-head comparison studies in first-episode schizophrenia used dose ranges of 1–6 mg/day risperidone versus 2.5–20 mg/day olanzapine, with similar response rates (54.3% vs 43.7%), supporting the approximate 1:3 to 1:4 conversion 4
• Receptor occupancy studies demonstrate that risperidone 3 mg achieves 72% D2 receptor occupancy, while olanzapine requires higher doses (10–15 mg) for comparable antipsychotic effect 5

Critical Safety Considerations When Converting

Extrapyramidal Symptom Risk

• Risperidone carries significantly higher EPS risk than olanzapine at equivalent doses 1
• Risperidone 2 mg can produce EPS even in non-elderly patients, whereas olanzapine 7.5 mg demonstrates minimal EPS risk 1
• Monitor closely for dystonia, akathisia, and parkinsonism when switching from olanzapine to risperidone 6

Metabolic Profile Differences

• Olanzapine 5 mg carries greater metabolic risk (weight gain, diabetes, dyslipidemia) than risperidone 1.5 mg 1, 4
• Weight gain at 4 months was 17.3% with olanzapine versus 11.3% with risperidone in comparative trials 4
• Metabolic monitoring becomes less urgent after switching from olanzapine to risperidone, though still necessary 1

Sedation and Timing

• Olanzapine is more sedating than risperidone at equivalent doses 1
• If the patient was taking olanzapine 5 mg at bedtime for sedation, risperidone 1.5 mg may provide insufficient sedative effect 1
• Consider split dosing of risperidone (e.g., 1 mg morning + 0.5 mg evening) to maintain 24-hour coverage while reducing peak-related side effects 6

Practical Switching Algorithm

For a stable patient on olanzapine 5 mg:

1. Initiate risperidone at 1.5 mg daily (or 1 mg if concerned about tolerability) 1
2. Cross-taper over 1–2 weeks: gradually reduce olanzapine while establishing risperidone 1
3. Monitor for symptom recurrence during the cross-taper, as risperidone may provide less stable response than olanzapine 4
4. Assess for new EPS within the first week, particularly akathisia and parkinsonism 6, 1
5. Do not exceed risperidone 4 mg/day in first-episode patients or 6 mg/day in chronic schizophrenia, as higher doses increase EPS without added efficacy 6, 5

Special Population Adjustments

Elderly Patients

• Maximum risperidone dose is 2–3 mg/day in elderly patients with dementia-related psychosis 1
• Start risperidone at 0.25 mg/day and titrate slowly, as EPS can occur at doses as low as 2 mg/day 6
• Avoid anticholinergics (benztropine) if EPS develop in elderly patients; instead reduce the risperidone dose 6

First-Episode Psychosis

• Do not exceed risperidone 4 mg/day in first-episode patients 6, 1
• A dose of 2 mg risperidone is considered mid-range and appropriate for most first-episode patients 1

Common Pitfalls to Avoid

• Do not use a 1:1 conversion ratio—this would result in severe underdosing (5 mg risperidone would be excessive for 5 mg olanzapine) 2
• Do not increase risperidone above 6 mg/day seeking additional efficacy, as EPS risk rises sharply without therapeutic benefit 6, 5
• Do not prophylactically prescribe benztropine when initiating risperidone; use only if EPS develop 6
• Do not abruptly discontinue olanzapine without cross-tapering, as symptom recurrence may occur 1
• Do not ignore the higher EPS risk with risperidone—patients stable on olanzapine may develop new motor side effects 1, 4